Clinical Trial Update: Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Tirellizumab combined with oral, IV, and intraperitoneal chemotherapy for gastric/gastroesophageal junction/esophageal adenocarcinoma w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Adenocarcinoma
• Gastric Cancer
• Gastroesophageal Junction Cancer
• Peritoneal Carcinomatosis

Drugs mentioned

• Tirellizumab (Tirellizumab)

Snippet

Sponsor: Fudan University | Conditions: Gastric Adenocarcinoma, Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING